Human pancreatic lipase-related protein 2: Tissular localization along the digestive tract and quantification in pancreatic juice using a specific ELISA

• Published in: Biochimica et biophysica acta 2006-10, Vol.1760 (10), p.1497-1504
• Main Authors: Eydoux, Cécilia, Aloulou, Ahmed, De Caro, Josiane, Grandval, Philippe, Laugier, René, Carrière, Frédéric, De Caro, Alain
• Format: Article
• Language: English
• Subjects: Amino Acid Sequence; Animals; Anti-peptide antibody; Calcinosis - metabolism; Classical pancreatic lipase; Colon - metabolism; ELISA; Enzyme-Linked Immunosorbent Assay - methods; Gastrointestinal Tract - chemistry; Humans; Life Sciences; Lipase - analysis; Lipase - biosynthesis; Lipase - immunology; Molecular Sequence Data; Pancreas - metabolism; Pancreatic juice; Pancreatic Juice - chemistry; Pancreatic lipase-related protein 2; Pancreatitis, Chronic - metabolism; Polyclonal antibody; Rabbits; Sensitivity and Specificity
• ISSN: 0304-4165; 0006-3002; 1872-8006
• DOI: 10.1016/j.bbagen.2006.06.005

Human pancreatic lipase-related protein 2 (HPLRP2) was previously found to be secreted by the exocrine pancreas. HPLRP2 shows a high level of activity on galactolipids, and might be involved in the digestion of these common vegetable lipids. Specific antibodies were raised in rabbits using a synthetic HPLRP2 peptide selected for its weak amino acid homology with the corresponding peptides of classical human pancreatic lipase (HPL) and human pancreatic lipase-related protein 1 (HPLRP1). ELISA and Western blotting data showed that these antibodies did not react with HPL or HPLRP1. Various tissues from the digestive tract were subjected to Western blotting analysis with the specific anti-peptide HPLRP2 antibody and the expression of HPLRP2 was detected in the pancreas and colon. An ELISA was developed for specifically measuring the HPLRP2 levels in pure pancreatic juice. This procedure was performed using the anti-peptide HPLRP2 antibody as the captor antibody and a biotinylated anti-HPLRP2 polyclonal antibody as the detector antibody. The lowest HPLRP2 quantification limit was found to be 50 μg/L and the reference range for the present assay was 50 μg–500 μg/L. HPL and HPLRP2 levels were measured using specific ELISAs in pancreatic juice from patients with and without pancreatic disorders. Patients with chronic calcifying pancreatitis (CCP) had significantly lower levels of both HPL and HPLRP2 than the controls subjects. The mean HPLRP2 to HPL ratio was estimated to be 28.30% (w/w) and 23.96% (w/w) in controls subjects and CCP patients, respectively, and the difference was not significant. The levels of HPL and HPLRP2 are therefore similarly reduced in both healthy patients and CCP patients.